desitin arzneimittel gmbh desitin pharma limited desitin arzneimittel...
Post on 12-Aug-2020
5 Views
Preview:
TRANSCRIPT
COMPANY PROFILE
COMPETENCE IN CNSDESITIN ARZNEIMITTEL GMBH
DESITIN PHARMA LIMITED
DESITIN ARZNEIMITTEL GMBH
OUR HERITAGE
Medium-sized, specialized
pharmaceutical company
• Founded nearly 100 years ago
in Berlin
• Independent, family-owned, profitable
company, based in Hamburg
• About 300 employees in development,
production, sales, medicine, marketing
and administration
• Established as a specialist in the
field of epilepsy
• Addition of further CNS indications
DESITIN ARZNEIMITTEL GMBH
FULLY INTEGRATED PHARMACEUTICAL COMPANY
Quality ControlProduction
Head Office
“White House”
Warehouse/Dispatching
DESITIN ARZNEIMITTEL GMBH
Incorporating Sales & Marketing, commercial, medical affairs and regulatory, full manufacturing and production lines and comprehensive distribution
STRONG REPUTATION IN CNS
COMPANIES WITH THE HIGHEST EXPERTISE
IN EPILEPSY IN GERMANY- 2013
Source: Medupha, 2013 (n=100 neurologists)
0
10
20
30
40
50
1 2 3 4 5 6 7 8
%
DESITIN
DESITIN ARZNEIMITTEL GMBH
STRONG REPUTATION IN CNS
COMPANIES WITH BEST SERVICE FOR THE
PHYSICIAN - 2013
COMPANIES WITH BEST SERVICE FOR
EPILEPSY PATIENTS IN GERMANY - 2013
DESITIN ARZNEIMITTEL GMBH
0
10
20
30
40
50
60
1 2 3 4 5 6 7 8
%
Source: Medupha, 2013 (n = 100 neurologists)
0
10
20
30
40
50
1 2 3 4 5 6 7 8
%
DESITIN
DESITIN
A SELECTION OF PRODUCTS
N3A/N4A Broad range of standard therapeutics
N3A: Epilepsy • N4A: Parkinson’s Disease M03AX: Dystonia •
L01XD04: Sensitizers used in photodynamic/radiation therapy
Antiepileptic with innovative
formulation
N3A
Innovative presentation
of a well-known antiepileptic
N3A
Innovative presentation
of a well-known antiepileptic
N3A
Antiepileptic drug (Orphan)
for severe myoclonic epilepsy
(Dravet Syndrome)
N3A
Antiparkinson drug (non-
ergoline dopamine agonist)
N4A
Indicated for the treatment
of dystoniaM03AX
Indicated for the treatment
of actinic keratosisL01XD04
DESITIN ARZNEIMITTEL GMBH
Only Orfiril® long and Levitiracetam Desitin® are marketed in the UK and under different brand names. Orfiril® long is marketed in the UK as Episenta® (sodium valproateprolonged release), Levetiracetam Desitin® is marketed in the UK as Desitrend® (levetiracetam). All other brands are not currently available in the UK.
TOTAL TURNOVER (Business Year: Oct 1st to Sep 30th)
International
Germany
0
10
20
30
40
50
60
70
80
90
100
2007/08 2008/09 2009/10 2010/11 2011/12 2012/13
Mil
lio
ns
€
96.5
7783
8993.5
99.5
DESITIN ARZNEIMITTEL GMBH
TURNOVER ACCORDING TO AREAS
Germany68%
Northern Europe11%
Western Europe8%Eastern Europe
10%
ROW3%
Fiscal Year 2012/13Total Turnover: 99.5 million €
DESITIN ARZNEIMITTEL GMBH
EUROPEAN TERRITORIES
DESITIN – A European CNS Force
KEY COUNTRIES(with own affiliates)
Germany, Norway, Denmark, Sweden,
Switzerland, Czech Republic, Slovakia,
Romania, UK, Estonia, Moldova
PARTNER COUNTRIES(with local distributors)
Austria, Belgium, Croatia, Finland, France,
Hungary, Iceland, Netherlands, Poland,
Portugal, Spain, Turkey
DESITIN ARZNEIMITTEL GMBH
DEDICATED TO EPILEPSY
• Offices located in Guildford,
Surrey
• The UK affiliate is a
fully-owned subsidiary of
Desitin Arzneimittel GmbH
DESITIN PHARMA LIMITED
• Product range for treatment of
epilepsy in a variety of different
formulations.
PRODUCTS AND FORMULATIONS
DESITIN PHARMA LIMITED
A VALUED PARTNER
• Reliable service-orientated partner
to physicians, pharmacists, patients
and their families
• Highly ethical and professional
company
• Member of the Ethical Medicines
Industry Group (EMIG)
• Open-minded mentality, flexible
in terms of business models and
innovative approaches
DESITIN PHARMA LIMITED
• ...with Key Opinion Leaders in key
University Hospitals and Clinical
Commissioning Groups (CCGs)
• Responsive to requests from
clinicians, specialist nurses,
pharmacists and patients
• Highly motivated – excellent team
spirit combined with hard-working,
positive ‘can-do’ attitude
• Excellent track record in innovative
drug delivery forms and new
Desitin product launches
PARTNERSHIP OF CHOICE...
Neurology
Paediatric
Psychiatry
DESITIN PHARMA LIMITED
THERAPY FOCUS & TARGETS
• Major therapeutic areas:
• Neurology
• Epilepsy
• Target KOLs and doctors:
• Current Field Force capacity
up to 7,000 calls per annum
• Regular field visits to:
• 200 Neurologists
• 60 Neuro-paediatricians
• 64 Epileptologists
• 250 Epilepsy Specialists Nurses
• 100 Hospital/CCG Pharmacists
• Regular management visits
to key stakeholders
DESITIN PHARMA LIMITED
148.673
246.797
328.811
489.111
585.685
769.127
892.918
989.643
£1,120.640
1,231,157
1,373,381
1,559,050
0
200
400
600
800
1000
1200
1400
1600
1800
Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13
Valu
e (
£’0
00s)
SALES HISTORY (£’000s)
DESITIN PHARMA LIMITED
NEW BUSINESS TARGETS
WE ADD VALUE IN THE
PROMOTION OF
SPECIALTY PRODUCTS
IN THE FIELD OF
EPILEPSY
WE SEEK NEW BUSINESS
OPPORTUNITIES IN
NEUROLOGY
DESITIN PHARMA LIMITED
TARGET GROUPS
• Neurologists
• Psychiatrists
• Paediatric specialists
• Neurosurgeons
• Hospital pharmacists
• CCG stakeholders
DESITIN PHARMA LIMITED
• In-licensing with exclusive rights
for sale
• Acquisition of products with potential
for sales growth or stabilisation
• Distribution Agreement (including
Marketing & Sales rights)
• Selected products
• Complete portfolio
• Co-Promotion
• Co-Marketing
NEW BUSINESS – POSSIBLE CO-OPERATION MODELS
DESITIN PHARMA LIMITED
www.desitin.co.uk
Mark InkerUK Managing Director
e-mail: inker@desitin.co.uk
Tel: +44 7771 870 190 (mobile)
Office Address:
Desitin Pharma Limited,
Unit 50,
Surrey Technology Centre,
40 Occam Road,
Surrey Research Park,
Guildford, Surrey GU2 7YG
CONTACTS
DESITIN PHARMA LIMITED
top related